Project information
Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
- Project Identification
- MSM0021622430
- Project Period
- 1/2007 - 12/2013
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Research Intents
- MU Faculty or unit
- Faculty of Medicine
- Other MU Faculty/Unit
- Faculty of Science
- Other MU Faculty/Unit
- Faculty of Informatics
- Other MU Faculty/Unit
- Central European Institute of Technology
- Keywords
- embryonic stem cells
The goal of this project will be a) to profit from availability of unique cellular resources - mouse and human embryonic stem cells and normal and malignant hematopoietic stem/progenitor cells, b) to effectively employ a wide variety of current and complementary methodologies available to the consortium, and c) to exploit a proven/certified expertise in working with various living systems that span from in vitro cultured cells, through animal models to oncohematological patients. All this together will represent a powerful experimental platform aimed at addressing a nature of molecules and molecular mechanisms underlaying phenomena that are common to both normal and cancer stem cells, mainly their ability to self-renew and to enter differentiation pathways. Integral part of this general goal is to implement multifaceted analytical approach that will cover studies of gene expression at both mRNA and protein levels, evaluating function of extra and intracellular signaling pathways, and analyzing biological properties of cells in vitro and in vivo. Expected outcome will be not only understanding but also a definition of molecules and/or molecular pathways to be tested as therapeutic targets, and cellular models that will make such testing feasible.
Publications
Total number of publications: 357
2012
-
A real-time (PCR) for a real life ...? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice
Experimental hematology, year: 2012, volume: 40, edition: 7, DOI
-
Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing Detection of the T315I Mutation in Bone Marrow CD34+Cells of a Patient with Chronic Myelogenous Leukemia 6 Months Prior to its Emergence in Peripheral Blood
Molecular Diagnosis & Therapy, year: 2012, volume: 16, edition: 3, DOI
-
Analýza mutací v genech pro mikroRNA u pacientů s chronickou lymfocytární leukémií.
Year: 2012, type: Conference abstract
-
Apoptosis in Chronic Myeloid Leukemia Cells Transiently Treated with Imatinib or Dasatinib Is Caused by Residual BCR-ABL Kinase Inhibition
Year: 2012, type: Conference abstract
-
Apoptosis inhibitor 5 (API-5; AAC-11; FIF) is upregulated in human carcinomas in vivo
Oncology Letters, year: 2012, volume: 3, edition: 4, DOI
-
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Leukemia & lymphoma, year: 2012, volume: 53, edition: 8, DOI
-
"Click & Seed" Approach to the Biomimetic Modification of Material Surfaces
Macromolecular Bioscience, year: 2012, volume: 12, edition: 9, DOI
-
Clonal selection of TP53 mutations in chronic lymphocytic leukaemia detected by ultra-deep pyrosequencing
Year: 2012, type: Conference abstract
-
Deep sequencing identifies TP53 mutations before their clonal selection by therapy in chronic lymphocytic leukemia
Year: 2012, type: Conference abstract
-
Detailed mutational analysis of TP53 gene reveals high INCI-dence of additional minor proportion mutations in chronic lymphocytic leukemia patients
Year: 2012, type: Conference abstract